As the President of CSA Medical , it is my pleasure to introduce you to our exciting endoscopic cryoablation technology that utilizes a liquid nitrogen spray to destroy unwanted tissue.

The technological features associated with the CryoSpray Ablation™ System are unprecedented for gastroenterology. To date, the energy source typically used to destroy unwanted GI tissue has been extreme thermal heat. Now, you have a SuperCool Choice™. At CSA Medical , we are committed to bringing the proven science of cryotherapy to unwanted lesions in the GI tract including Barrett’s esophagus. Over the past ten years, we have worked closely with clinicians and investigators to design an elegant cryosurgical device that exceeds the expectations of today’s advanced endoscopists. While at national and international meetings we heard your colleagues share their enthusiasm for the CSA™ System. Like you, your colleagues were impressed by the System’s ability to visually direct a low-pressure cryospray to treat both focal and broad lesions. Equally compelling will be the extraordinary patient care benefits you will observe when destroying unwanted tissue with extreme cold in your patients with Barrett’s esophagus.

The CryoSpray Ablation™ System is currently available for clinicians in the United States and Europe. If you are interested in receiving more information about the CSA System, please contact me by email at info@csamedical.com. A member of our product team will contact you shortly. In the meantime, please browse our website for important clinical and reimbursement information for your review and consideration.

Again, thank-you for your time and interest in CSA Medical and our pioneering CryoSpray Ablation™ Treatment of pre-cancerous and cancerous lesions in the GI tract. We are excited about the possibility of adding this proprietary technology to your care for Barrett’s esophagus.

Tim Askew
President/CEO
CSA Medical, Inc.